Human Immunodeficiency Virus | Current Treatment | EU5 | 2016
The HIV therapy market is growing as a result of the uptake of new premium-priced antiretroviral agents, particularly the latest single-tablet regimens (STRs) with improved side-effect profiles that place an emphasis on safety and tolerability. Our Current Treatment content provides deep insights drawn from a survey of 253 infectious disease specialists, internal medicine physicians, and general practitioners in the EU5 regarding the current and anticipated use of HIV regimens, including the recently approved STR Genvoya (elvitegravir/emtricitabine/tenofovir alafenamide/cobicistat), by capturing patient- and market-share data, current prescribing trends, and anticipated changes in prescribing and treatment behavior.
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
Report
Chronic Obstructive Pulmonary Disease – Current Treatment – Current Treatment: Physician Insights – Chronic Obstructive Pulmonary Disease (EU5)
The treatment landscape for chronic obstructive pulmonary disease (COPD) has significantly evolved in the past few years. A plethora of COPD treatments are available in the EU5. These include long-…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (including IBS without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by altered bowel motility, stool consistency, and frequency, and is classified into constipation-predominant,…
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Breast Cancer (US)
The increasing focus on biomarkers has reshaped the treatment paradigm in oncology, allowing physicians to tailor treatments to subpopulations of patients diagnosed with breast cancer, NSCLC and…
